NL-OMON27414尚未招募不适用
A multicenter, double-blinded, randomised, 12 month, parallel group study to compare the efficacy of 48 mg BETahistine versus 8 [three times per day, tid] in the treatment of vertigo attacks in MENière's disease.
Prof. Dr. P.P.G. van Benthem (November 2015)Functie/ Position: Hoogleraar Keel-, neus-, oorheelkunde │Opleiding/Education: Studierichting/ Subject:T: +31 55 844 8207 │ F: +31 55 581 8194 │E: p.van.benthem@gelre.nl Prof. Dr. P.P.G. van Benthem (november 2015)University Medical Centre LeidenHead Otorhinolaryngolgy and Head- and Neck Surgery P.O. Box 96002300 RC Leiden0 个研究点目标入组 74 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 74
研究概览
简要总结
ot applicable
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Unilateral MD (definite or probable) according to diagnostic criteria derived from the American Academy Otolaryngology Head and Neck Surgery, Classification Committee of the Bárány Society, European Academy of Otology and Neurotology and International Classification of Vestibular Disorders published in 2015.
- •2. Age > 18 years at the start of the trial.
排除标准
- •1.Bilateral MD.
- •2.Severe disability (e.g. neurological, orthopedic, cardiovascular) or serious concurrent illness that might interfere with treatment or follow-up.
研究者
相似试验
尚未招募
不适用
FAIR-study.Chronic Obstructive Pulmonary DiseaseNL-OMON23638CROMSOURCE – Quality System Certified ISO 9001Lange Dreef 11H, NL-4131 NJ Vianen, The Netherlands144
进行中（未招募）
1 期
Trial to assess the effects of rimonabant 20 mg in patients with abdominal obesity and microalbuminuria, with type 2 diabetes mellitus or dyslipidaemia with or without other cardiometabolic risk factors.EUCTR2006-002951-33-ESsanofi-aventis, S.A.550
进行中（未招募）
不适用
A 12 week multi-centre, randomized, double-blind, placebo controlled evaluation of the most efficacious and tolerable dose of escitalopram in the treatment of elderly patients. - Double-blind placebo controlled study of escitalopram in the treatment of depression in the elderlyDepression in the elderlyEUCTR2005-003821-25-DKPsychiatric Hospital189
进行中（未招募）
1 期
A 12-week multicentre, randomised, double-blind, parallel group, Phase IIpilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mgbid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtinecitrate 400 mg bid (800 mg/d) versus placebo in the treatment of patientswith Stress Urinary Incontinence (SUI)Stress Urinary IncontinenceEUCTR2005-000107-33-ESaboratorios Dr. Esteve, S.A.180
进行中（未招募）
不适用
A 12-week multicentre, randomised, double-blind, parallel group, Phase IIpilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mgbid (400 mg/d), cizolirtine citrate 300 mg bid (600 mg/d) and cizolirtinecitrate 400 mg bid (800 mg/d) versus placebo in the treatment of patientswith Stress Urinary Incontinence (SUI)Stress Urinary IncontinenceEUCTR2005-000107-33-SEaboratorios Dr. Esteve, S.A.180